Merck scraps centerpiece of $2.7B ArQule buy after late-stage safety concerns

3d Vector Yellow warning sign with Exclamation mark concept. Eps 10 Vector.

iStock, Thx4Stock

Merck is canning multiple Phase 3 studies of nemtabrutinib after a benefit-risk review derailed hopes of the asset entering the non-covalent BTK inhibitor race.

Merck is ending development of an experimental oral BTK inhibitor after identifying safety risks, a move that includes shuttering several late-stage studies.

The asset, known as nemtabrutinib or MK-1026 and picked up in the $2.7 billion buyout of ArQule at the end of 2019, was being evaluated in a series of hematology studies making up Merck’s BELLWAVE program. The New Jersey pharma shared Tuesday evening that the entire program would be discontinued, including three Phase 3 studies.

The decision stems from an external recommendation from a data monitoring committee that reviewed findings from the late-stage BELLWAVE-011 trial for patients with untreated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). Merck launched the trial in 2023 and expected to recruit 1,200 patients, with a primary readout slated for 2032.

The data committee suggested that the potential benefits of nemtabrutinib may not outweigh the risks in the study. Merck “subsequently confirmed this following a review of the data in its totality” and also decided to terminate the broader program, the company said in the release.

That includes shuttering the BELLWAVE-008 trial for certain patients with CLL/SLL and BELLWAVE-010 for second-line advanced CLL/SLL.

On its third-quarter earnings investor call Thursday morning, Merck executives touted recent pipeline wins alongside a strong performance for subcutaneous Keytruda and pulmonary arterial hypertension drug Winrevair that drove the pharma’s overall sales expectations to surpass expectations.

The non-covalent BTK inhibitor, formerly known as ARQ 531, was the centerpiece of the ArQule deal. At the time, the asset had demonstrated a manageable safety profile and early signs of anti-tumor activity in a Phase 1 study.

The acquisition gave Merck a spot in the BTK inhibitor race after Eli Lilly’s $8 billion buy of Loxo Oncology. In early 2023, Lilly gained accelerated approval in mantle cell lymphoma for the Loxo-discovered Jaypirca—the first FDA-approved non-covalent BTK inhibitor to reach the market. The drug later received expanded approval for CLL/SLL.

Jaypirca’s label warns about the risk of infections, bleeding, low blood cell counts, abnormal heart rhythms, new cancers, liver damage and embryo-fetal toxicity.

Merck’s discontinuation comes as the pharma braces for looming patent expiries for its blockbuster cancer therapy Keytruda. Patent losses starting in 2028 will put $33 billion in revenue at risk, according to a September report from BMO. But analysts have been largely bullish on the company’s plans to replace the key revenue stream, highlighting the Moderna-partnered mRNA cancer vaccine intismeran autogene, Winrevair for a rare form of high blood pressure in the lungs and the TROP2 antibody drug conjugate sac-TMT as its strongest potential growth products.

BMO Capital Markets is more impressed by Merck’s plans to replace lost Keytruda revenue than on Bristol Myers Squibb’s efforts to fill the expected void that will come from loss of exclusivity for both Opdivo and Eliquis.

Gabrielle Masson is an award-winning biopharma editor and writer with more than seven years of journalism experience in life sciences and healthcare. Subscribe to the daily GenePool and weekly Manufacturing Brief newsletters she curates here, and contact her at gabrielle.masson@biospace.com.

MORE ON THIS TOPIC